Early and severe cytokine release syndrome (CRS) is a unique complication of T replete haploidentical transplantation, when post-transplant cyclophosphamide (PTCy) is employed as GVHD prophylaxis without preceeding immunosuppression. This phenomenon has been reported with greater frequency and severity following a mobilised peripheral blood stem cell (PBSC) graft. We report on the incidence, severity and outcome of CRS in 157 patients undergoing PTCy-based haploidentical transplantation.

中文翻译：

---

CTLA4Ig限制了单倍体外周血干细胞移植后早期细胞因子释放综合征的发生率和严重性。

当采用移植后环磷酰胺（PTCy）预防GVHD且未进行免疫抑制时，早期和严重的细胞因子释放综合征（CRS）是T完全单倍体移植的独特并发症。据报道，在动员的外周血干细胞（PBSC）移植后，这种现象的发生频率和严重性更高。我们报告了157例接受基于PTCy的单倍体移植的患者中CRS的发生率，严重性和结局。